The COVID-19 Technology Access Pool (C-TAP) is a single platform for the developers of COVID-19 health products – vaccines, tests, medical devices and treatments – to share their know-how, intellectual property (IP), and data with quality-assured manufacturers in order to boost the global supply and accelerate the end to the pandemic.
C-TAP, so far endorsed by nearly 45 Member States, is based on public health-oriented, transparent, voluntary, and non-exclusive licences, which could be issued through the Medicines Patent Pool, a C-TAP partner.
Such licences aim to provide the qualified manufacturers with: